Alzheimer's Early Detection: Managing Dementia in India

Dementia has emerged as a major public health challenge across India. Currently, approximately 8.8 million older adults in the country live with dementia. Furthermore, researchers expect this clinical burden to double within the next decade. In this setting, Alzheimer's early detection is essential for timely clinical intervention and improved patient outcomes. When clinicians identify cognitive changes early, they can introduce interventions that delay functional decline and preserve daily independence.

Why Alzheimer's Early Detection Matters in Clinical Practice

Clinicians face significant diagnostic hurdles when evaluating cognitive concerns in aging adults. Frequently, families dismiss insidious memory loss as normal aging. However, subtle changes in executive function and memory warrant immediate diagnostic attention. Sedentary lifestyles, uncontrolled diabetes, and cardiovascular disorders significantly accelerate neurodegenerative processes in Indian patients. Therefore, physicians must proactively screen vulnerable populations during routine health encounters. Early evaluation allows medical teams to address reversible causes of impairment. In addition, it enables structured discussions regarding care plans and lifestyle modifications before profound neurodegeneration occurs.

Differentiating Benign Forgetfulness from Neurodegenerative Disease

Importantly, not every patient presenting with memory complaints suffers from irreversible dementia. Dr Sahil Kohli highlights that routine lifestyle stressors frequently disrupt cognitive performance. For instance, chronic sleep deprivation, severe emotional stress, and multitasking often mimic cognitive impairment. Consequently, primary care physicians must distinguish between transient cognitive lapses and progressive neurodegenerative illness. A thorough clinical assessment should incorporate objective neuropsychological testing and targeted laboratory investigations. Moreover, clinicians must screen for thyroid abnormalities, metabolic deficiencies, and depressive disorders. As a result, practitioners can reassure healthy individuals while identifying those who require specialized neurological evaluation.

Disease-Modifying Therapies: Navigating Lecanemab and Donanemab

The therapeutic landscape has recently transformed with novel disease-modifying monoclonal antibodies. Agents such as Eisai's lecanemab and Lilly's donanemab target underlying amyloid pathology. Specifically, lecanemab clears soluble amyloid protofibrils every two weeks. In contrast, donanemab targets established insoluble amyloid plaques in a monthly regimen. However, both treatments require confirmed biomarker evidence of amyloid pathology prior to infusion. Clinicians must confirm amyloid status using cerebrospinal fluid analysis or amyloid positron emission tomography. Furthermore, these agents only benefit patients in the early stages, specifically mild cognitive impairment or mild dementia. Later-stage disease still relies entirely on symptomatic therapy and caregiver support. In addition, treating neurologists must vigilantly monitor patients with magnetic resonance imaging for amyloid-related imaging abnormalities.

Frequently Asked Questions

Q1: Who is eligible for novel disease-modifying therapies in Alzheimer's disease?

Only patients with mild cognitive impairment or mild dementia with confirmed amyloid pathology qualify for these targeted therapies.

Q2: How do lecanemab and donanemab differ in administration?

Lecanemab requires intravenous infusions every two weeks, whereas clinicians administer donanemab as a monthly infusion.

Q3: Can routine lifestyle stress cause noticeable memory problems?

Yes. Chronic sleep deficits, intense emotional stress, and multitasking frequently cause transient forgetfulness without indicating dementia.

References

1. Experts call for increasing Alzheimer’s awareness for early detection andtreatment - ETHealthworld
2. Lee J, et al. Prevalence of dementia in India: National and state estimates from a nationwide study. Alzheimers Dement. 2023.
3. Chaudhuri A. Lecanemab and Donanemab in Early Alzheimer's Disease: A Systematic Review of Clinical, Biomarker, and Safety Outcomes. CHRISMED J Health Res. 2026.